| 產(chǎn)品編號 | bs-1405R-Bio |
| 英文名稱1 | Rabbit Anti-HNF1A/Biotin Conjugated antibody |
| 中文名稱 | 生物素標記的肝細胞核因子1α抗體 |
| 別 名 | HNF1A; TCF1; HNF1 alpha; HNF-1 Alpha; Hepatocyte nuclear factor 1 Alpha; Albumin proximal factor; Hepatic nuclear factor 1 alpha; Hepatic nuclear factor 1; Hepatic transcription factor 1 alpha; Hepatic transcription factor 1; HNF 1; HNF 1A; HNF1A; Interferon production regulator factor; LF B1; LF B1 hepatic nuclear factor; LFB 1; LFB1; LFB1 hepatic nuclear factor; Liver specific transcription factor LF B1; Liver specific transcription factor LFB1; Maturity onset diabetes of the young 3; MODY 3; MODY3; TCF 1; TCF1; TCF-1; Transcription factor 1; Transcription factor 1 hepatic; HNF1A_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 免疫學 信號轉導 轉錄調節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Mouse, Rat, (predicted: Chicken, Dog, Pig, Cow, Zebrafish, Sheep, ) |
| 產(chǎn)品應用 | WB=1:50-200 ELISA=1:100-1000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 67kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human HNF1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: IRF1 encodes interferon regulatory factor 1, a member of the interferon regulatory transcription factor (IRF) family. IRF1 serves as an activator of interferons alpha and beta transcription, and in mouse it has been shown to be required for double-stranded RNA induction of these genes. IRF1 also functions as a transcription activator of genes induced by interferons alpha, beta, and gamma. Further, IRF1 has been shown to play roles in regulating apoptosis and tumor-suppressoion. Function: Transcriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver. Required for the expression of several liver specific genes. Binds to the inverted palindrome 5'-GTTAATNATTAAC-3'. Subunit: Binds DNA as a dimer. Interacts with PCBD1. Heterotetramer with PCBD1; formed by a dimer of dimers. Subcellular Location: Nucleus. [ALTERNATIVE PRODUCTS] Event=Alternative splicing; Named isoforms=3; Name=A; IsoId=P20823-1; Sequence=Displayed; Name=B; IsoId=P20823-2; Sequence=VSP_002250, VSP_002251; Name=C; IsoId=P20823-3; Sequence=VSP_002252, VSP_002253. Tissue Specificity: Liver. DISEASE: Hepatic adenomas familial (HEPAF) [MIM:142330]: Rare benign liver tumors of presumable epithelial origin that develop in an otherwise normal liver. Hepatic adenomas may be single or multiple. They consist of sheets of well-differentiated hepatocytes that contain fat and glycogen and can produce bile. Bile ducts or portal areas are absent. Kupffer cells, if present, are reduced in number and are non-functional. Conditions associated with adenomas are insulin-dependent diabetes mellitus and glycogen storage diseases (types 1 and 3). Note=The disease is caused by mutations affecting the gene represented in this entry. Bi-allelic inactivation of HNF1A, whether sporadic or associated with MODY3, may be an early step in the developmant of some hepatocellular carcinomas. Maturity-onset diabetes of the young 3 (MODY3) [MIM:600496]: A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease. Note=The disease is caused by mutations affecting the gene represented in this entry. Diabetes mellitus, insulin-dependent, 20 (IDDM20) [MIM:612520]: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Similarity: Belongs to the HNF1 homeobox family. Contains 1 homeobox DNA-binding domain. Database links: Entrez Gene: 6927 Human Entrez Gene: 21405 Mouse Omim: 142410 Human SwissProt: P20823 Human SwissProt: P22361 Mouse Unigene: 654455 Human Unigene: 332607 Mouse Unigene: 9660 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 轉錄調節(jié)因子（Transcriptin Regulators） |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
